NCT01695135View on ClinicalTrials.gov

A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

August 9, 2012

Primary Completion Date

June 20, 2014

Study Completion Date

May 8, 2018

Conditions
Prostate Neoplasms
Interventions
DRUG

Abiraterone acetate

Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily

DRUG

Placebo

Placebo (4 tablets) taken orally once daily

DRUG

Prednisone

Prednisone 5 mg tablet taken orally twice daily

Trial Locations (11)

Unknown

Beijing

Changsha

Chongqing

Guangzhou

Hangzhou

Nanjing

Shanghai

Suzhou

Tianjin

Wenzhou

Wuhan

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01695135 - A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy | Biotech Hunter | Biotech Hunter